Pharma's Market
SPECIAL REPORT
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Should Homeowners Be Able To Walk Away From Mortgage?
- Dubai Markets Open Sharply Lower for Second Day
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Nov. 30: Unusual Volume Leaders
- Notre Dame Fires Charlie Weis After 5 Seasons
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Oil Demand Sees Year-Over-Year Rise, First Since 2007
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
- GE, Vivendi Agree to Value NBCU Stake at $5.8 Billion
- Tuesday's ISM in Focus as Bulls Call for Turn in Dollar
- Dubai Markets Open Sharply Lower for Second Day
- Dubai World to Restructure About $26 Billion of Debt
- Cramer: Dubai Can’t Sink These 6 Dividend Stocks
- White House to Crank Up Pressure on Mortgage Industry
- Treasury Threatens Banks, Not Borrowers
- Good Sign for the Economy: 'Greed' Makes a Comeback
- The World's Biggest Debtor Nations
PHARMA'S MARKET VIDEO
RSS FEED
Text Size 
CNBC Correspondent
On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck [MRK
Loading...
()
] and the company it's buying, Schering-Plough [SGP
Loading...
()
], are sliding. So, what gives?
Well, Bernstein analyst Dr. Tim Anderson put out a MRK-SGP research note this morning titled, "Caveat Emptor," and he did a voicemail blast to clients this morning saying he was "sounding the alarm bells once again."
He's writing and talking about the upcoming presentation of data from a study called "Arbiter 6" comparing MRK and SGP's cholesterol-fighter Zetia to Niaspan from Abbott Labs [ABT
Loading...
()
]. Zetia is also used to make Vytorin along with the statin Zocor. They're big-selling drugs. Researchers will unveil the study results in a so-called "late-breaking clinical trial" session at the American Heart Association's annual meeting in Orlando on Monday, November 16th, at 10:45 a.m. ET. A "late breaker" is prominent, prestigious status that scientific and medical meetings typically grant to big, important studies. They're often done in the biggest convention hall before the largest audience.
Dr. Anderson also says the study will be published simultaneously in a major medical journal, most likely the "New England Journal of Medicine," along with an editorial or two. And he says one of the opinion pieces will be "pretty scathing by a well-known critic." Any guesses? Hmm, lemme think.
Dr. Anderson doesn't think there's anything, as he put it, "truly wrong" with Zetia or Vytorin, but for whatever reason he believes the drugs are "being attacked by some pretty fierce critics." Long-term he still likes Merck together with Schering, but in the near-term he says, "Buyer beware."
On Merck's most recent conference call company officials were already revving up the spin machine. They promised that they will be at AHA in full force messaging docs, so-called key opinion leaders and, of course, the media. I wonder if they'll send the big guns to talk to us.
Disclosures: Someone who lives with one of the Bernstein pharma researchers owns Merck stock. And a part of Bernstein owns at least one percent of MRK and SGP shares.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes